| A Review of Immunotherapy in Non-Small-Cell Lung Cancer MP Capella, SA Pang, MA Magalhaes, K Esfahani Current Oncology 31 (6), 3495-3512, 2024 | | 2024 |
| PARPi eligibility amongst women with newly diagnosed invasive breast cancer enrolled in the GREAT universal genetic testing study. SM Wong, Z Rezoug, SP Totten, DM Szlachtycz, AM Atayan, K Mohler, ... Journal of Clinical Oncology 42 (16_suppl), 531-531, 2024 | | 2024 |
| Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates. SA Pang, M Flores Molina, P Thébault, Y Zheng, H Chou, C Goncalves, ... Journal of Clinical Oncology 42 (16_suppl), 12031-12031, 2024 | | 2024 |
| Sarcopenia predicts short‐term treatment‐related toxicity in patients undergoing curative‐intent therapy for head and neck cancer: A systematic review and meta‐analysis MA Mascarella, J Ferdus, V Vendra, S Sridharan, K Sultanem, C Tsien, ... Head & Neck 46 (6), 1500-1509, 2024 | 1 | 2024 |
| Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer IAF Muniz, M Araujo, J Bouassaly, F Farshadi, M Atique, K Esfahani, ... International Journal of Molecular Sciences 25 (7), 4009, 2024 | | 2024 |
| A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine MP Capella, K Esfahani Current Oncology 31 (4), 1913-1919, 2024 | | 2024 |
| Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature Medicine 30 (2), 604-604, 2024 | | 2024 |
| Differences in Management Between Dermatologists and Oncologists for Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors S Oliel, R Bierbrier, K D'Aguanno, K Esfahani, K Pehr Journal of Cutaneous Medicine and Surgery 28 (1), 79-81, 2024 | | 2024 |
| Quality of life after neoadjuvant chemotherapy and transoral robotic surgery for oropharynx cancer JA Silver, N Bouganim, K Richardson, M Henry, MA Mascarella, ... JAMA Otolaryngology–Head & Neck Surgery 150 (1), 65-74, 2024 | 4 | 2024 |
| An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors R Bierbrier, K D’Aguanno, S Oliel, Y Zeng, K Esfahani, K Pehr Journal of Cutaneous Medicine and Surgery 27 (6), 614-620, 2023 | | 2023 |
| 1250 Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: a case-control study with translational correlates SA Pang, MF Molina, P Thébault, H Chou, C Goncalves, P Nunes Filho, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Systemic anticancer therapy and thromboembolic outcomes in hospitalized patients with cancer and COVID-19 S Gulati, CY Hsu, S Shah, PK Shah, R Zon, S Alsamarai, J Awosika, ... JAMA oncology 9 (10), 1390-1400, 2023 | 2 | 2023 |
| Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature medicine 29 (8), 2121-2132, 2023 | 91 | 2023 |
| Survey of oncologists and dermatologists in Canada on the management of Acneiform eruptions induced by epidermal growth factor receptor inhibitors R Bierbrier, K Esfahani, K Pehr Journal of Cutaneous Medicine and Surgery 26 (6), 624-625, 2022 | 1 | 2022 |
| A New Era: Immunotherapy Applied to Contemporary Cardiovascular Practice S Filimon, C Pop, M Chetrit, K Esfahani, M Hudson, J Rouleau, ... The Canadian journal of cardiology 38 (10), 1629-1633, 2022 | | 2022 |
| Demographics, outcomes, and risk factors for patients with sarcoma and COVID-19: a CCC19-Registry based retrospective cohort study MJ Wagner, C Hennessy, A Beeghly, B French, DP Shah, S Croessmann, ... Cancers 14 (17), 4334, 2022 | 4 | 2022 |
| Fecal microbiota transplantation followed by anti–PD-1 treatment in patients with advanced melanoma. WH Miller, B Routy, R Jamal, DS Ernst, D Logan, K Esfahani, K Belanger, ... Journal of Clinical Oncology 40 (16_suppl), 9533-9533, 2022 | 11 | 2022 |
| Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers C Calabrese, K Esfahani, L Calabrese ARTHRITIS & RHEUMATOLOGY 73, 3177-3177, 2021 | 1 | 2021 |
| Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report K Esfahani, MHH Berg, H Zargham, R Billick, K Pehr, M Redpath, ... Journal for immunotherapy of cancer 9 (3), 2021 | 6 | 2021 |
| Moving towards personalized treatments of immune-related adverse events K Esfahani, A Elkrief, C Calabrese, R Lapointe, M Hudson, B Routy, ... Nature reviews Clinical oncology 17 (8), 504-515, 2020 | 228 | 2020 |
